Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Antibe Therapeutics Inc (ATE.TO)

Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Antibe Therapeutics Inc 15 Prince Arthur Avenue Toronto ON M5R 1B2 CAN

https://www.antibethera.com P: 905-570-5103

Description:

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Key Statistics

Overview:

Market Capitalization, $K 15,638
Shares Outstanding, K 53,009
Annual Sales, $ 0 K
Annual Net Income, $ -19,475 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,213 K
60-Month Beta -0.19
% of Institutional Shareholders 0.00%

Growth:

1-Year Return -47.32%
3-Year Return -93.36%
5-Year Return -90.78%

Per-Share Information:

Next Earnings Date 07/04/24
Earnings Per Share ttm -0.35
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 12/01/20

ATE.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -53.63%
Return-on-Assets % -28.53%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 0.60
Book Value/Share 0.49
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar